Anaxis Pharma

Anaxis Pharma is an innovative Australian biotech startup founded in 2017, specializing in small molecule drug discovery for necroptotic cell death and inflammatory diseases. The company's focus on developing novel inhibitors and modulators targeting necroptosis addresses the unmet medical needs of patients with chronic inflammatory diseases such as irritable bowel disease, Crohn’s disease, liver fibrosis, and reperfusion injury.

As a joint venture between Synthesis Research and the Walter and Eliza Hall Institute of Medical Research, Anaxis Pharma benefits from the extensive expertise of the Institute and the medicinal chemistry capabilities of SYNthesis Research. The company has successfully attracted funding from major pharmaceutical companies for two of its pre-clinical programs, positioning it uniquely to advance these programs to the clinic rapidly.

Anaxis Pharma operates within the biotechnology and healthcare industries, aiming to leverage its innovative approach to address critical medical conditions. The company's strategic partnerships and cutting-edge research make it an attractive prospect for investors seeking opportunities in the biotech sector.